BMS's Opdivo meets in Chinese Phase III for second-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said the Phase III CheckMate -078 trial of Opdivo nivolumab (BMS-936558, MDX-1106, ONO-4538) to treat stage IIIb/IV non-small cell lung cancer was stopped

Read the full 271 word article

User Sign In